Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy
This study shows that CP-GEP has the potential to stratify patients with early-stage melanoma who did not undergo SLNB based on their risk of recurrence. Patients with CP-GEP Low Risk have a significantly better long-term survival. CP-GEP shows to be promising for guiding SLNB referral and may support melanoma care by optimizing personalized treatment plans and potential surveillance regimens.
Authors
- Tobias Sinnberg (ORCID: https://orcid.org/0000-0003-3922-3327)
- Jvalini Dwarkasing
- Stephan Forchhammer (ORCID: https://orcid.org/0000-0002-1274-2613)
- Eftychia Chatziioannou (ORCID: https://orcid.org/0000-0002-7843-7160)
- Alexander M.M. Eggermont (ORCID: https://orcid.org/0000-0002-4278-040X)
- Teresa Amaral (ORCID: https://orcid.org/0000-0002-2516-5181)
- Tim Arentsen
- Ulrike Leiter (ORCID: https://orcid.org/0000-0002-8019-1577)
- Heike Niessner (ORCID: https://orcid.org/0000-0002-2542-7022)
- Rikje Ruiter (ORCID: https://orcid.org/0000-0002-8107-2924)
- Lukas Flatz (ORCID: https://orcid.org/0000-0001-9683-8390)
- Alica Nuebling
- Lena Nanz
Institutions
- University of Tübingen (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.ejca.2025.115372
- Citations
- 11
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.50